anti-CD70 CAR NK cell therapy（Argenx BV）

N/A

Report date: 2022/07/13 14:21:18

Base Information

Drug Nameanti-CD70 CAR NK cell therapy（Argenx BV）
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionAnti-CD70
TargetsCD70 antigen
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesArgenx BV
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of AntwerpArgenx BV
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A